Non-small cell lung cancer (NSCLC), which represents 80–85% of lung cancer cases, is one
of the leading causes of human death worldwide. The majority of patients undergo an …

Despite a growing interest in development of non-cytotoxic targeted agents, systemic
chemotherapy is still the mainstay of treatment for both non-small cell lung cancer (NSCLC) …

Lung cancer is the most commonly diagnosed cancer in the world.“Driver” and “passenger”
mutations identified in lung cancer indicate that genetics play a major role in the …

The discovery of genetic alterations, that can be targeted therapeutically, has launched a
new era for lung cancer research and personalized therapy. However, not all the identified …

Resistance to chemotherapy drugs is a major problem in cancer treatment. Scientific
advances made in the last two decades have resulted in the identification of genes and …

Introduction Several targetable genetic alterations have been identified in non-small cell
lung cancers (NSCLC) and drugs targeting these alterations have been approved for the …

Management of patients with lung cancer continues to pose a considerable challenge to
today's oncologist. While treatment may be curative in the early stages of the disease, the …

Non-small-cell lung cancer (NSCLC) constitutes about 85% of all lung cancers.
Approximately 50% of patients diagnosed with NSCLC present with advanced disease …

Simple Summary Despite an initial response to therapy, many lung cancer patients
inevitably develop resistance to therapy leading to decreased duration of response and …

The advent of precision medicine has brought light to the treatment of non-small cell lung
cancer (NSCLC), expanding the options for patients with advanced NSCLC by targeting …